非常规 T 细胞的原位编程

← 返回前沿论文

非常规 T 细胞的原位编程

英文原题：In situ programming of unconventional T cells.

PubMed 2026/08/14（内容时间） Trends Biotechnol Q1 · IF 16.6（JCR 2025）

技术：NK 细胞技术：γδ T 细胞技术：NKT 细胞实体瘤地区：美国

登录后收藏与关注全文解读加入对比

研究概要

非常规T细胞（UTCs），包括γδ T细胞、黏膜相关恒定T细胞和自然杀伤T细胞，通过半恒定T细胞受体以不依赖人类白细胞抗原的方式识别保守的非肽抗原，使其成为广泛适用免疫疗法的有吸引力的候选者。

中文摘要

非常规T细胞（UTCs），包括γδ T细胞、黏膜相关恒定T细胞和自然杀伤T细胞，通过半恒定T细胞受体以不依赖人类白细胞抗原的方式识别保守的非肽抗原，使其成为广泛适用免疫疗法的有吸引力候选者。然而，其临床转化仍受限于激活的时空控制不佳、功能性耗竭以及体内组织归巢不足，尤其是在实体瘤中。基于生物材料的递送系统提供了一种有前景的策略，通过在病变组织内实现UTC配体、细胞因子和核酸的局部和持续递送，来克服这些障碍。通过对UTC反应进行精确的原位编程，这些平台可能提高治疗疗效和安全性。本综述总结了当前基于生物材料的策略，并讨论了在人类癌症中原位UTC编程的新兴机遇。

展开英文摘要原文

Unconventional T cells (UTCs), including γδ T cells, mucosal-associated invariant T cells, and natural killer T cells, recognize conserved nonpeptide antigens through semi-invariant T cell receptors in an human leukocyte antigen-independent manner, making them attractive candidates for broadly applicable immunotherapies. However, their clinical translation remains limited by poor spatiotemporal control of activation, functional exhaustion, and insufficient tissue homing in vivo, particularly in solid tumors. Biomaterial-based delivery systems provide a promising strategy to overcome these barriers by enabling localized and sustained delivery of UTC ligands, cytokines, and nucleic acids within diseased tissues. Through precise in situ programming of UTC responses, these platforms may enhance therapeutic efficacy and safety. This review summarizes current biomaterial-based strategies and discusses emerging opportunities for in situ UTC programming in human cancers.

论文信息

作者: Li YR、Nan H、Yang Y、Wang S、Yang L
第一作者单位: Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: charlie.li@ucla.edu.United States
通讯作者单位: Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: liliyang@ucla.edu.United States
文献类型: 综述
期刊: Trends in biotechnology2026 Aug 14

原文标识: PubMed 42601274　·　DOI 10.1016/j.tibtech.2026.07.027

在 PubMed 查看 → 出版商原文（DOI）报告译文或资料问题 →